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Abstract: Background: Hearing loss remains an important global health problem that is potentially
addressed through early identification of a genetic etiology, which helps to predict outcomes of
hearing rehabilitation such as cochlear implantation and also to mitigate the long-term effects of
comorbidities. The identification of variants for hearing loss and detailed descriptions of clinical
phenotypes in patients from various populations are needed to improve the utility of clinical genetic
screening for hearing loss. Methods: Clinical and exome data from 15 children with hearing loss were
reviewed. Standard tools for annotating variants were used and rare, putatively deleterious variants
were selected from the exome data. Results: In 15 children, 21 rare damaging variants in 17 genes
were identified, including: 14 known hearing loss or neurodevelopmental genes, 11 of which had
novel variants; and three candidate genes IST1, CBLN3 and GDPD5, two of which were identified in
children with both hearing loss and enlarged vestibular aqueducts. Patients with variants within IST1
and MYO18B had poorer outcomes after cochlear implantation. Conclusion: Our findings highlight
the importance of identifying novel variants and genes in ethnic groups that are understudied for
hearing loss.
Keywords: anomalies; CBLN3; cochlear implant; enlarged vestibular aqueduct; GDPD5; genetic
testing; hearing loss; inner ear; IST1; malformations; temporal bone
1. Introduction
Hearing loss remains a public health burden worldwide, with global measures of the
effects of hearing disability remaining steady over the past three decades [1]. With the
use of sequencing technologies in the clinical setting, identification of genetic variants that
predispose to congenital or early childhood hearing loss is becoming more accessible to a
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larger segment of the world population. When partnered with newborn hearing screening,
massively parallel DNA sequencing holds the promise of identifying the genetic cause(s)
of hearing loss at the earliest stage and can therefore guide the clinician in diagnosing and
treating comorbidities, planning rehabilitative options such as hearing aids or cochlear
implantation (CI), and when they become available, applying gene therapies [2,3]. Genetic
hearing loss is a highly heterogeneous disease both in terms of clinical presentation and
pathogenic DNA variants, which are usually rare and may lie within any one of hundreds
of genes [2,4]. The identification of variants for hearing loss and their corresponding clinical
profiles in patients from various populations will contribute to the large body of knowledge
that is required to improve the utility of clinical genetic screening for hearing loss. A large
community of clinicians and scientists continues to identify novel genes and variants for
syndromic and nonsyndromic hearing loss. In the past two years alone, variants within
novel hearing loss genes including SLC9A3R1, ANLN, FOXF2, TOP2B, PLS1, PISD, CLRN2,
AP1B1, SCD5, GGPS1, SLC12A2, THOC1 and GREB1L were identified in patients of various
ethnicities [5–22]. To date, some of these genes remain candidates that require replication
in additional hearing loss families and patients [6,9,14,19].
Compared to hundreds of known hearing loss genes, studies on the genetic causes
of temporal bone malformations are limited, with only a few genes identified so far, to
name a few: EVA and/or Mondini dysplasia and SLC26A4; superior semicircular canal
dehiscence (SSCD) or posterior semicircular canal dehiscence (PSCD) and CDH23; and
variable cochleovestibular anomalies in some patients with variants in GJB2, POU3F4,
SOX10, CHD7, SIX1 and GREB1L [20–29]. Prior knowledge of temporal bone malforma-
tions is important not only to prepare the surgeon for potential complications during CI
but also to prognosticate outcomes after surgery [29–31]. Because CI is performed as early
as three months old, occurrence of temporal bone anomalies might also be predicted earlier
if genetic testing is performed at neonatal stage.
We previously studied a cohort of Filipino patients with hearing loss requiring
CI [32–34]. In this cohort, we identified variants in known hearing loss genes in half of the
patients, including a recurrent variant SLC26A4 c.706C>G (p.Leu236Val) that was associ-
ated with bilaterally enlarged vestibular aqueducts (EVA) [32–34]. Of eleven patients with
previously identified non-SLC26A4 variants, only three had inner ear anomalies, including:
EVA in a patient with an EYA4 variant; and SSCD in one patient with a KCNQ4 variant, and
in another patient with CHARGE syndrome due to a CHD7 variant [32,34]. On the other
hand, of the genetically unsolved cases, 75% had temporal bone anomalies (Table 1) [33].
In this study, we reviewed the clinical and exome data of Filipino cochlear implantees and
identified 12 novel variants in known genes for hearing loss and/or neurodevelopmental
syndromes, as well as three candidate genes for hearing loss.
Table 1. Clinical data for 15 Filipino children with hearing loss requiring cochlear implants (CI).
ID Age at CI (yr) Sex Temporal Bone Findings Clinical History Gene
1 3.95 M EVA, L
Bilateral small choroidal
fissure cysts and a probable
neuroepithelial cyst or
prominent perivascular space





incomplete cochlear turns, B.
EVA, L.
Global developmental delay LMX1A
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Table 1. Cont.
ID Age at CI (yr) Sex Temporal Bone Findings Clinical History Gene
5 3.84 F HJB with dehiscence, L
Prenatal antibiotic use for
maternal respiratory infection.






6 10.81 M PSCD + HJB, B. EVA, R. Pneumonia, sinusitis, andprogressive hearing loss PTPRQ
7 8.00 F HJB, L. OM, L.
Mild motor delay and
hypotonia. History of urinary




8 3.03 M SSCD, L U/R COL11A1; TECTA
9 8.19 F EVA, L




13 5.95 M Normal Global developmental delay SLC12A2








canals, B. Absent cochlear and
inferior vestibular nerves, R.
Maternal diabetes at 6 months
gestation MYO18B
20 14.59 F Normal
Fluctuating hearing loss with
steeply sloping audiogram




22 4.40 F Normal U/R GREB1L; CBLN3
23 4.61 F Normal U/R CDH23; MYO18B
24 6.10 M EVA, B
Fever, jaundice, foul umbilical





27 7.72 F EVA, B. OM, L. U/R GDPD5
M, male; F, female; U/R, unremarkable; B, bilateral; L, left; R, right; EVA, enlarged vestibular aqueduct; HJB, high jugular bulb; OM, otitis
media; PSCD, posterior semicircular canal dehiscence; SSCD, superior semicircular canal dehiscence.
2. Materials and Methods
Out of our initial cohort of 30 Filipino patients, we previously identified a genetic vari-
ant as causal of hearing loss in 15 patients [32–34]. For this study, we reviewed the clinical
records and temporal bone images of 15 Filipino cochlear implantees for whom no variants
in known hearing loss genes were identified previously (Table 1) [34]. High-resolution
computed tomography with 2–3 mm axial cuts and without contrast was performed using
a Siemens Somatom Plus 4 CT Scanner in order to document temporal bone anomalies.
DNA samples were submitted for exome sequencing at the University of Washington
Northwest Genomics Center, as previously described [33,34]. The Roche NimbleGen Se-
qCap EZ Human Exome Library v.2.0 (~37 Mb target) was used for sequence capture,
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and sequencing was performed using an Illumina HiSeq to an average depth of 30 ×.
Fastq files were aligned to the hg19 human reference sequence using Burrows-Wheeler
Aligner, generating demultiplexed .bam files [35]. The Genome Analysis Tool Kit was
used for realignment of indel regions (IndelRealigner), variant quality score recalibration
(VQSR) and variant detection and calling, as well as generation of standard metrics used
for quality control (QC) during exome analyses [36]. Low-quality and likely false-positive
variants were flagged. The initial .vcf file for 29 GJB2-negative individuals included 82,853
variants, of which 74,965 passed QC filters. Variants from the entire .vcf file were annotated
using ANNOVAR (annovar.openbioinformatics.org, last accessed March 18, 2021) [37].
Indels from the exome sequence data were also annotated using MutationTaster [38], how-
ever no rare or low-frequency variants were identified as potentially deleterious in the
15 patients studied.
Single nucleotide variants that passed QC were initially selected if they: (a) were
homozygous or heterozygous in the 15 children with no known genetic etiology of hear-
ing loss; (b) were stop, splice or missense variants; (c) had a minor allele frequency
(MAF) <0.005 in any gnomAD (gnomad.broadinstitute.org, last accessed 31 March 2021),
1000 Genomes or Greater Middle East (GME) Variome population [4,39,40]; (d) from the
Combined Annotation Dependent Depletion (CADD; cadd.gs.washington.edu, last ac-
cessed 31 March 2021) pre-computed scores database, had a scaled CADD score of≥15 [41];
and (e) was predicted to be deleterious by at least one bioinformatics tool from db-
SNFP41a [42]. Variants were excluded if they were common across our cohort, particularly
if occurring within genes not previously associated with hearing loss but are found in
multiple individuals that were identified to have variants in known genes for hearing
loss [32–34]. This selection strategy resulted in a shorter list of 2570 variants, which was
parsed further by prioritizing any variant that: (a) lies within a known hearing loss gene;
(b) is a loss-of-function variant; (c) lies within a potentially novel gene but is homozygous
or with two variants in the same gene in the same individual; and/or (d) lies within a gene
that is identified in a mouse model with hearing loss. A list of 120 variants were rechecked
against equivalent hg38 databases. Additional MAF checking was performed using the
GenomeAsia 100K database (genomeasia100k.org, last accessed March 31, 2021) [43]. For
known hearing loss genes, variants were ruled out if they occurred in a gene in which phe-
notypes are expressed only in homozygous or compound heterozygous individuals and the
patient genotype is heterozygous. For the final list of 89 variants (Table S1), the Integrative
Genomics Viewer v2.8.3 was used to visualize variants from exome sequence data [44].
3. Results
Of the 15 children studied, six had EVA, three with high jugular bulb (HJB), two
with SSCD/PSCD and two with malformed cochleae (Figure 1; Table 1). Five children
had normal temporal bone CT/MRI images. From clinical history, seven children had
exposures to infections and antibiotics, whether prenatally, at the neonatal stage or during
early childhood (Table 1), suggesting that the previous infections or antibiotic use may have
also played a role in their hearing loss etiology. Prior to CI, hearing loss in the 15 children
was congenital, prelingual and severe-to-profound across frequencies, except for: (a) ID6
who had progressive hearing loss; and (b) ID20 who had fluctuating hearing loss with a
steeply sloping audiogram and profound hearing loss at the high frequencies (Table 1).
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ID7 with the heterozygous MYO7A variant plus potentially compound heterozygous PCDH15 and CDH23 variants has 
HJB (asterisk) on the left. There is also fluid in the middle ear space (marked by X), indicating otitis media. (F,G) ID8 with 
the heterozygous COL11A1 and TECTA variants has left-sided superior semicircular canal dehiscence (SSCD, hash sign). 
(H,I) ID19 with the heterozygous MYO18B c.2555C>T (p.(Ala852)) variant has multiple congenital inner ear anomalies 
with bilaterally malformed cochleae, vestibules and semicircular canals (plus signs), as well as absence of the right cochlear 
and inferior vestibular nerves. 
A total of 21 rare/low-frequency potentially deleterious variants were identified in 17 
genes (Tables 1 and 2), all of which are known to be expressed in the mouse cochlea 
(gEAR, umgear.org, last accessed March 31, 2021). Although majority of the variants were 
heterozygous with likely autosomal dominant (AD) inheritance, several variants had 
seemingly different modes of inheritance, such as: (1) a homozygous CLDN9 variant in 
ID20; (2) potentially compound heterozygous variants in GDPD5, PCDH15 and/or CDH23 
in three children; and (3) an X-linked variant in FLNA in male patient ID24 (Table S1). 
While our knowledge of mode of inheritance of these variants is limited, for five individ-
uals the available history matches either an autosomal recessive (AR) pattern or AD in-
heritance with decreased penetrance (Table S1). A more detailed genotype-phenotype cor-
relation per gene and patient is hereby presented. 
DSPP: Variants in DSPP (MIM 125485; 4q22.1) were first identified as a cause of AD 
hearing loss DFNA39 with dentinogenesis (MIM 605594) in Chinese families with den-
tinogenesis imperfecta 1 and adult-onset progressive sensorineural high-frequency hear-
ing loss [45]. Additional hearing loss families, all of East Asian ethnicity, have been iden-
tified to have splice or missense variants within the first five exons of DSPP [46–48]. In the 
reported families, there was variability in age of onset, affected hearing frequencies, se-
verity of hearing loss, and symptoms of tinnitus or balance problems [45–48]. In one fam-
ily, the affected individuals had congenital hearing loss and bilateral cochlear defects with 
or without EVA [47]. In our study, patient ID1 had congenital hearing loss and unilateral 
EVA (Table 1; Figure 1). He was heterozygous for a novel variant c.730G>A 
Figure 1. Temporal bone images in six patients with hearing loss. (A) ID1 with the heterozygous DSPP c.730G>A
(p.( ly244 rg)) variant has enlarged vestibular aqueduct (EVA, arrow) on the left. (B,C) ID3 with the heterozygous LMX1A
and COL2A1 variants h s bilater lly malformed cochleae wit incomplete chlear turns (plus signs) and left-sided EVA
(arrow). (D) ID5 ith the heterozygous DMXL2 variant has a high jugular bulb (HJB, asterisk) on the left. (E) ID7 with the
heterozygous MYO7A variant plus potentially compound heterozygo s PCDH15 and CDH23 variants has JB (asterisk) on
the left. There is also fluid in the middle ear space (marked by X), indicating otitis media. (F,G) ID8 with the heterozygous
COL11A1 and TECTA variants has left-sided superior semicircular canal dehiscence (SSCD, hash sign). (H,I) ID19 with
the heterozygous MYO18B c.2555C>T (p.(Ala852)) variant has multiple congenital inner ear anomalies with bilaterally
malformed cochleae, vestibules and semicircular canals (plus signs), as well as absence of the right cochlear and inferior
vestibular nerves.
A total of 21 rare/low-frequency potentially deleterious variants were identified in
17 genes (Tables 1 and 2), all of which are known to be expressed in the mouse cochlea
(gEAR, umgear.org, last accessed March 31, 2021). Although majority of the variants
were heterozygous with likely autosomal dominant (AD) inheritance, several variants had
seemingly different modes of inheritance, such as: (1) a homozygous CLDN9 variant in
ID20; (2) potentially compound heterozygous variants in GDPD5, PCDH15 and/or CDH23
in three children; and (3) an X-linked variant in FLNA in male patient ID24 (Table S1). While
our knowledge of mode of inheritance of these variants is limited, for five individuals the
available history matches either an autosomal recessive (AR) pattern or AD inheritance
with decreased penetrance (Table S1). A more detailed genotype-phenotype correlation
per gene and patient is hereby presented.
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Table 2. Novel variants and candidate genes 1 for hearing loss and temporal bone anomalies.
ID Gene Variant rsID gnomAD GenomeAsia 100kSEA 2 Scaled CADD
Damaging Results from
dbNSFP Tools
1 DSPP NM_014208: c.730G>A(p.(Gly244Arg)) 1044690454 NA 0.0014 24.3 FA,mLR,mSVM, MT,PP2,SI
3 LMX1A NM_177398: c.606G>C(p.(Leu202Phe)) NA NA NA 24.8
FA,LRT,mLR,
mSVM,MT,PP2, PR,SI
5 DMXL2 NM_015263: c.257T>C(p.(Leu86Ser)) 761692429 OTH: 0.0005 NA 24.1 LRT,MT,PP2,SI























7, 18 MYO7A NM_000260: c.4921G>A(p.(Glu1741Lys)) 767975012 EAS: 0.0002 0.003 26.2 LRT,MT,PP2,PR
8 COL11A1 NM_080629: c.4364A>C(p.(Lys1455Thr)) 769350133 EAS: 0.0004 NA 28.6
FA,LRT,mLR,
mSVM,MT,PP2, PR,SI
8 TECTA NM_005422: c.2967C>A(p.(His989Gln) 200821009 EAS: 0.003 0.0014 20.4
FA,LRT,mLR,
mSVM,MT,PP2, PR,SI
9 IST1 NM_001270976: c.737C>G(p.(Pro246Arg)) 774343604 EAS: 0.0002 NA 24.0 LRT,MT,PP2,PR, SI
13 SLC12A2 NM_001046: c.2977G>T(p.(Glu993*)) NA NA NA 60.0 MT
19 MYO18B NM_032608: c.2555C>T(p.(Ala852Val)) NA NA NA 26.1
FA,LRT,mLR,
mSVM,MA,MT, PP2,PR,SI
23 MYO18B NM_032608: c.1982G>A(p.(Trp661*) 372939044 AFR: 0.0005 NA 44.0 LRT/MT
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Table 2. Cont.
ID Gene Variant rsID gnomAD GenomeAsia 100kSEA 2 Scaled CADD
Damaging Results from
dbNSFP Tools
20 CLDN9 NM_020982: c.75C>G(p.(Cys25Trp)) 368045321 OTH: 0.0005 0.004 20.6
FA,LRT,MA,mLR,
mSVM,MT,PP2, PR,SI
20, 24 FLNA NM_001110556: c.6350A>G(p.(Asn2117Ser)) 375205247 EAS: 0.002 NA 20.2 FA,LRT,MT,PR










745585758; 373413383 ME: 0.003; AFR:0.00002
0 (South Asia =
0.0007); NA 23.1; 24.8
LRT,MT,PP2;
LRT,MA,MT,PP2
1. Bold font denotes candidate genes, while novel variants in known genes are in italics. 2. Variants identified in the Southeast Asian (SEA) population in the GenomeAsia 100k database were mostly from
individuals of Filipino (n = 52) or Indonesian (n = 68) descent. MAF from Filipino alleles were identified in indigenous Negrito (Ati, Aeta) tribes, which are usually intermarried and are not representative of
the general Filipino population. NA, not available/found; EAS, East Asian; AFR, African; ME, Middle Eastern; OTH, other; FA, FATHMM; LRT, likelihood ratio test; mLR, meta-logistic regression; mSVM,
meta-support vector machine; MA, MutationAssessor; MT, MutationTaster; PP2, PolyPhen2; PR, PROVEAN; SI, SIFT.
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DSPP: Variants in DSPP (MIM 125485; 4q22.1) were first identified as a cause of
AD hearing loss DFNA39 with dentinogenesis (MIM 605594) in Chinese families with
dentinogenesis imperfecta 1 and adult-onset progressive sensorineural high-frequency
hearing loss [45]. Additional hearing loss families, all of East Asian ethnicity, have been
identified to have splice or missense variants within the first five exons of DSPP [46–48]. In
the reported families, there was variability in age of onset, affected hearing frequencies,
severity of hearing loss, and symptoms of tinnitus or balance problems [45–48]. In one
family, the affected individuals had congenital hearing loss and bilateral cochlear defects
with or without EVA [47]. In our study, patient ID1 had congenital hearing loss and
unilateral EVA (Table 1; Figure 1). He was heterozygous for a novel variant c.730G>A
(p.(Gly244Arg)), which lies within exon 4 of DSPP (Table 2). Although we have no record
of dental abnormalities, he had small cysts identified in his brain MRI (Table 1). Dspp
is expressed in inner ear, brain and pericytes of blood vessels in dental pulp of mice,
and also in zebrafish otoliths [45,49,50]. He also has additional variants in ANLN (MIM
616027; 7p14.2), ZNF462 (MIM 617371; 9q31.2), and CEP290 (MIM 610142; 12q21.32).
Each of these three genes harbor variants previously associated with hearing loss in
various syndromes (Table S1): branchio-otic syndrome with ossicular chain anomalies for
ANLN [6]; Weiss-Kruszka syndrome with craniofacial dysmorphisms and developmental
delay for ZNF462 [51]; and Joubert syndrome with cerebral, retinal and kidney disease for
CEP290 [52]. While we cannot rule out if ID4′s brain cysts are related to these syndromic
genes (e.g., kidney cysts are common in individuals with CEP290 variants) [52], the other
features of these syndromes are absent in patient ID1. Overall, the DSPP variant in ID6 fits
his inner ear findings.
LMX1A: In addition to hearing loss, ID3 has malformed cochleae, left-sided EVA and
global developmental delay (Figure 1; Table 1). Both the hearing loss and bony cochlear
defects may be explained by novel heterozygous variants in two genes, namely LMX1A
(MIM 600298; 1q23.3) c.606G>C (p.(Leu202Phe)) and/or COL2A1 (MIM 120140; 12q13.11)
c.3569G>A (p.(Arg1190His)) (Table 2 and Table S1). LMX1A is known for AD or AR
nonsyndromic hearing loss [53,54], while COL2A1 is related to Stickler syndrome type 1
with hearing loss (MIM 108300) as well as various skeletal phenotypes [55]. Homozygous
Lmx1a-mutant mice lack endolymphatic ducts and have short cochlear ducts [56], which
seem to recapitulate the incomplete cochlear turns and EVA in patient ID2. Additionally,
hair cell loss and disorganization were seen in the cochleae of mutant mice [57]. However,
unlike the deaf homozygous mice, the Lmx1a-heterozygous mice had normal hearing [56].
In contrast, two Dutch families with heterozygous missense LMX1A variants had mild-
to-profound hearing loss of variable onset from infancy to adulthood [53]. On the other
hand, a transgenic Col2a1-mutant mouse model had a smaller misshapen otic capsule
as well as craniofacial abnormalities such as cleft palate and short mandible [58]; these
latter features were not found in our patient ID3. In patient ID3, two variants in USH2A
(MIM 608400; 1q41) were previously ruled out due to high MAF in the general Filipino
population and lack of retinitis pigmentosa after years of follow-up (Table S1). There were
three other interesting variants in ID3 (Table S1): (a) heterozygous missense variant in
ZFHX4 (MIM 606940; 8q21.13)–ZFHX4 is one of two genes within the minimum region of
overlap in patients with 8q21 microdeletions manifesting with intellectual and develop-
mental disability, sensorineural hearing loss, craniofacial anomalies and hypotonia [59,60];
(b) heterozygous missense variant in NRP1–the Nrp1+/− mouse has abnormal auditory
brainstem responses (ABR), progressive hearing loss, disorganized outer spiral bundles
and enlarged microvessels of the stria vascularis [61]; and (c) a hemizygous missense
variant in ARHGAP4 (MIM 300023; Xq28), in which missense variants were previously
described in children with intellectual disability [62,63]. This case shows potential overlap
of clinical presentation due to multiple deleterious variants, of which the LMX1A variant
is the strongest etiology of inner ear abnormalities in this patient while the ZFHX4 or
ARHGAP4 variants may explain ID3′s developmental delay.
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DMXL2: DMXL2 (MIM 612186; 15q21.2) was recently identified to have missense vari-
ants causing AD nonsyndromic hearing loss in Chinese and Cameroonian families [64,65].
In these families, the affected individuals were mostly adult with progressive hearing
loss and no reported temporal bone abnormalities, although one Cameroonian child had
congenital profound hearing loss [65]. Our patient ID5 has a novel heterozygous DMXL2
variant c.257T>C (p.(Leu86Ser)) (Table 2). In addition to prelingual profound hearing loss,
her temporal bone CT showed a left HJB with evidence of dehiscence (Figure 1). She also
had a history of neonatal infection as well as pervasive developmental delay (Table 1). In
mice, cochlear expression of Dmxl2 is limited to the hair cells and spiral ganglion neu-
rons [64], and Dmxl2-knockout leads to preweaning lethality in the homozygous mouse
and decreased bone mineral content if heterozygous (International Mouse Phenotyping
Consortium (IMPC), www.mousephenotype.org, last accessed March 31, 2021). It is pos-
sible that the temporal bone findings are also an effect of the Dmxl2 variant in ID5′s case.
Biallelic loss-of-function DMXL2 variants are also known to cause Ohtahara syndrome
characterized by neurologic deficits including intellectual disability, developmental delay,
hearing loss, polyneuropathy and also facial dysmorphisms [66]. However because patient
ID5 only has a heterozygous DMXL2 variant, the developmental delay may also be due
to other causes, such as variants in CCDC186 (MIM 619249; 10q25.3), ZRF2 or MCM3AP
(MIM 603294; 21q22.3) (Table S1).
PTPRQ: PTPRQ (MIM 603317; 12q21.3) is a known cause of AD (MIM 617663) or AR
(MIM 613391) nonsyndromic hearing loss in families and probands with multiple ethnic-
ities, which may be variable in clinical presentation [67,68]. Patient ID6 is heterozygous
for a novel missense variant c.6179T>C (p.(Val2060Ala)) within PTPRQ (Table 2). He also
has progressive hearing loss, bilateral PSCD and HJB and right-sided EVA as temporal
bone findings, as well as previous pneumonia and sinusitis (Table 1). In general previ-
ous reports of PTPRQ-related hearing loss excluded temporal bone anomalies, however
narrowed internal auditory canals were found in a Chinese proband with compound
heterozygous PTPRQ variants [69]. We previously ruled out a heterozygous variant in
TCOF1 (MIM 606847; 5q32-q33) due to lack of clinically diagnosed craniofacial hallmarks
of AD Treacher-Collins syndrome (MIM 154500), but upon review, we cannot rule out
that the TCOF1 variant also contributes to hearing loss and temporal bone anomalies, as
was previously described (Table S1) [70]. Lastly a heterozygous variant in DNAH14 (MIM
603341; 1q42.12), a candidate gene for primary ciliary dyskinesia and lung function in
cystic fibrosis (Table S1) [71,72], may play a role in ID6′s susceptibility to airway infections.
PCDH15, CDH23 and MYO7A: While these three genes are known for Usher syndrome,
they have AR nonsyndromic forms of hearing loss. In addition, MYO7A (MIM 276903;
11q13.5) variants may be inherited in an AD manner, while digenic inheritance for PCDH15
(MIM 605514; 10q21.1) and CDH23 (MIM 605516; 10q22.1) were demonstrated in mice
and humans [73]. ID7 has hearing loss, HJB, mild motor delay, hypotonia, and urinary
and upper respiratory infections (Figure 1; Table S1). She has multiple variants of interest,
but the strongest findings are compound heterozygous PCDH15/CDH23 variants plus a
heterozygous MYO7A variant (Table 2). Interestingly, the same MYO7A variant c.4921G>A
(p.(Glu1461Lys)) is heterozygous in another patient ID18, who has nonsyndromic hearing
loss (Table 2). This may suggest that the additional variants in ID7 contribute to her
variable phenotype (Table S1). Patient ID23 also has nonsyndromic hearing loss and three
CDH23 variants, however we could not confirm if these CDH23 variants are compound
heterozygous or inherited in cis due lack of available parental DNA (Table 2). These
CDH23 and MYO7A variants are reported as variants of unknown significance (VUS) in
ClinVar (www.ncbi.nlm.nih.gov/clinvar/, last accessed 31 March 2021), while the PCDH15
c.3787C>T (p.(Pro1263Ser)) variant is novel.
COL11A1: ID8 has hearing loss, left-sided SSCD, and heterozygous missense variants in
two genes known for AD nonsyndromic hearing loss, namely COL11A1 (MIM 120280; 1p21.1)
and TECTA (MIM 602574; 11q23.3) (Tables 1 and 2; Figure 1). Of the two deleterious variants,
the COL11A1 c.4364A>C (p.(Lys1455Thr)) variant is rarer (gnomAD EAS MAF = 0.0004). Pre-
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vious reports on COL11A1 or TECTA did not reveal inner ear abnormalities in patients with
variants [74,75].
IST1: ID9 with profound hearing loss and left-sided EVA is heterozygous for a
c.737C>G (p.(Pro246Arg)) variant in IST1 (MIM 616434; 16q22.2). This rare deleterious
variant (Table 2) was singled out due to a heterozygous Ist1 mouse model that had abnor-
mal ABR in early adulthood (IMPC). In mouse cochlea, Ist1 is expressed in both hair cells
and supporting cells (gEAR). Recently de novo VPS4A variants were identified to cause a
multi-systemic neurodevelopmental disorder including sensorineural hearing loss due to
the abnormal accumulation of IST1 protein in the limiting membrane of proband-derived
fibroblasts and also in neuronal endosomes [76], suggesting that proper localization of
IST1 is required for neuronal function. Taken together, our findings make IST1 an excellent
candidate gene for nonsyndromic hearing loss. Moreover, ID9 had poor CI outcomes, such
as average CI-aided hearing threshold of 74 dB and speech tests using PEACH scores at
10–21%. Identification of additional patients with IST1 variants is needed to verify these
CI outcomes.
SLC12A2: ID13 who has hearing loss and global developmental delay is heterozygous
for a novel stop variant c.2977G>T (p.(Glu993*)) in SLC12A2 (also NKCC1; MIM 600840;
5q23.3) (Tables 1 and 2). SLC12A2 variants have been identified in patients with AD
nonsyndromic hearing loss (MIM 619081), with AD Delpire-McNeill syndrome (MIM
619083), or AR Kilquist syndrome (MIM 619080). Recently McNeill et al. identified
heterozygous SLC12A2 variants in eight mostly pediatric patients with intellectual disability
or developmental delay, and ~60% had bilateral sensorineural hearing loss [18]. Previous
homozygous knockout of Slc12a2 in mice led to loss of hearing and vestibular function,
collapse of Reissner’s membrane, disorganization of the organ of Corti, and loss of hair
cells and supporting cells [77]. On the other hand, heterozygous deletion of Slc12a2 in
mice resulted in early hearing loss that progressed with age despite normal inner ear
morphology and histology [78].
MYO18B: Two patients had variants in MYO18B (MIM 607295, 22q12.1). Patient
ID23 with nonsyndromic hearing loss has potentially compound heterozygous CDH23
variants and also a novel heterozygous MYO18B variant c.1982G>A (p.(Trp661*)) (Table 2).
The other patient ID19 has another novel variant c.2555C>T (p.(Ala852Val)) and severe
cochleovestibular defects (Figure 1). In patient ID19, no other strong candidate variants
or genes were identified (Table S1). MYO18B variants were previously associated with
autosomal recessive Klippel-Feil syndrome (MIM 616549) which is characterized by ne-
maline myopathy, facial dysmorphisms and hearing loss in up to 60% of patients [79].
Heterozygous Myo18b-knockout mice had abnormal ABR findings (IMPC), further support-
ing the role of heterozygous MYO18B variants in the etiology of hearing loss. Patients with
hearing loss as part of Klippel-Feil syndrome were also diagnosed with inner ear dysplasias
including internal acoustic canal deformities [80], which are similar to the temporal bone
anomalies found in patient ID19 (Figure 1). Of the 30 Filipino patients, ID19 and ID23
who carry MYO18B variants had poorer outcomes after CI, with PEACH scores whether in
quiet or noise at 4–37% despite average post-CI thresholds of ~40 dB at 0.25–8 kHz. This
is not unexpected given potential cochlear nerve defects [30,31] that might not have been
diagnosed radiologically (Figure 1). For ID19, her PEACH scores improved to >80% after
5 years of continued use of her implant on the left ear.
FLNA: The same FLNA (MIM 300017; Xq28) variant c.6350A>G (p.(Asn2117Ser)) that is
classified as VUS in ClinVar was identified in two children ID20 and ID24 (Table 2). ID24 is
male, hemizygous for the FLNA variant and has no other rare damaging variants in hearing
loss genes. He is hemizygous for a known pathogenic variant in G6PD (MIM 305900; Xq28)
which may explain his neonatal jaundice (Table 1 and Table S1). FLNA is associated with
multiple disorders, of which frontometaphyseal dysplasia (MIM 305620), Melnick-Needles
syndrome (MIM 309350) and otopalatodigital syndrome (MIM 311300/304120) have been
reported to include sensorineural hearing loss. ID24 has EVA in addition to the hearing loss
but has no detailed assessment of additional skeletal anomalies; meanwhile temporal bone
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anomalies have been reported previously in a patient with Melnick–Needles syndrome [81].
On the other hand, the female patient ID20 who is heterozygous for the same FLNA variant
has additional variants as the cause of hearing loss (Table S1).
CLDN9: ID20 has fluctuating hearing loss at the high frequencies and additional
sinonasal findings (Table 1). In addition to the FLNA variant, she is homozygous for a
novel variant c.75C>G (p.(Cys25Trp)) in CLDN9 (MIM 615799; 16p13.3) and heterozygous
for ANKRD11 (MIM 611192; 16q24.3) (Table 2 and Table S1). KBG syndrome (MIM 148050)
due to heterozygous ANKRD11 variants manifests variably as macrodontia, intellectual
disability and skeletal/craniofacial defects, including conductive or mixed hearing loss–
these features do not fit the patient’s clinical presentation [82]. In contrast, a CLDN9
frameshift variant was found in a Turkish family with AR nonsyndromic, progressive high-
frequency hearing loss [83]; this clinical description is similar to that of ID20. In Cldn9-/-
mice, defective tight junctions in the cochlea are hypothesized to cause the increased
concentration K+ in the perilymph and massive hair cell loss [84]. In this case the sinonasal
findings are probably not related to genetic susceptibility.
GREB1L: Previously variants in GREB1L (MIM 617782; 18q11.1-q11.2) were associated
with AD nonsyndromic hearing loss with or without cochleovestibular malformations and
non-ear phenotypes [20–22]. Our patient ID22 is heterozygous for a novel missense variant
GREB1L c.3798C>G (p.(Ser1266Arg)) but has no other features in addition to profound
hearing loss (Table 1, Table 2 and Table S1). She also has a heterozygous variant in CBLN3
(MIM 612978; 14q12). Cbln3 is expressed in supporting cells and outer hair cells of the inner
ear (gEAR), and also in the cerebellum and dorsal cochlear nucleus [85]. Heterozygous
Cbln3-mutant mice have abnormal ABR (IMPC), implying that CBLN3 is also a candidate
gene for ID22′s hearing loss.
GDPD5: Patient 27 has two missense variants each in two genes: GDPD5 (also GDE2,
MIM 609632; 11q13.4-q13.5) which encodes an enzyme involved in glycerol metabolism;
and MADD (MIM 603584; 11p11.2) (Table S1). Gdpd5 is expressed in hair cells and sup-
porting cells of mouse cochlea (gEAR) and homozygous knockout mice have abnormal
ABRs (IMPC). On the other hand, biallelic MADD variants cause a multisystemic neu-
rodevelopmental disorder that includes sensorineural hearing loss in 17% of patients [86].
Our patient ID27 has hearing loss and bilateral EVA with no note of additional neurologic
phenotypes (Table 1), suggesting that GDPD5 is a candidate gene for her hearing loss.
4. Discussion
In this study, we identified novel variants in 14 genes: twelve are novel variants in
eleven known hearing loss or neurodevelopmental genes DSPP, LMX1A, DMXL2, PTPRQ,
PCDH15, COL11A1, TECTA, SLC12A2, MYO18B, CLDN9 and GREB1L; while four variants
are in candidate genes for hearing loss IST1, CBLN3 and GDPD5 (Table 2). In addition,
several inner ear and temporal bone malformations were identified in variant carriers,
namely: (1) EVA in carriers of DSPP, IST1, FLNA and GDPD5 variants; (2) semicircular canal
dehiscence in carriers of DMXL2, PTPRQ and COL11A1/TECTA variants; and (3) malformed
cochleae in carriers of variants in LMX1A and MYO18B (Table 1; Figure 1). These findings
suggest that at least some of these variants (e.g., variants in DSPP, LMX1A and MYO18B)
are also potentially causal of temporal bone anomalies. Factors that may have contributed
to an increased rate of variant identification from the sequence data of our cohort of
30 pediatric cochlear implant recipients include: (a) a more inclusive approach for low-
frequency variants, particularly if the MAF was increased in an indigenous or isolated
population which has high rates of intermarriage and potentially undiagnosed hearing
loss (Table 2) [43,87,88]; and (b) genotype-phenotype correlation that takes into account
additional clinical manifestations (e.g., developmental delay, recurrent infections) which
overlap with features of syndromes or multi-systemic neurodevelopmental disorders. In
the latter case, hearing loss might not be among the major criteria of the disorder, but
the overall clinical presentation of the specific patient may fit previous descriptions of
genotype-phenotype correlations that include hearing loss or bony defects.
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Apparent contradictions in modes of inheritance may be due to undetected second
variants for autosomal recessive disorders, which is a limitation of our study due to the
lack of data on CNVs, cryptic splice sites, and non-coding regions [89]. Unfortunately, we
only have DNA samples from patients and not from parents or additional relatives, so we
cannot determine the identified variants’ pattern of inheritance or if they potentially arose
de novo.
It is not unusual for the same gene to cause both autosomal dominant and autosomal
recessive forms of hearing loss, e.g., MYO7A (MIM 276903) variants have been associated
with either autosomal dominant (MIM 601317) or autosomal recessive non-syndromic
hearing loss (MIM 600060), as well as autosomal recessive Usher syndrome type 1B (MIM
276900). Differences in modes of inheritance may be associated with phenotypic variability,
such that variants known to cause autosomal recessive hearing loss that is characterized by
prelingual profound hearing loss co-exist with heterozygous variants that cause autosomal
dominant forms with milder hearing loss of later onset. Additionally, with the increasing
number of identified genes for hearing loss, the occurrence of multiple variants within
different genes that independently predispose to hearing loss in the same individual may
be more common than previously thought [90]. Multiple variants in different genes may
also contribute to variability in phenotypes (e.g., two genes with variants in the same
individual causing different phenotypes rather than the same syndrome). An example
would be ID24 in our cohort, in which a known pathogenic G6PD variant likely explains
the patient’s neonatal jaundice, while the hearing loss is potentially due to a known variant
in FLNA. Continued efforts in identifying novel genes mean that patient sequence data
must be periodically reanalyzed not only to resolve a potential genetic etiology, but also
to identify compound phenotypes due to variants in multiple genes. If multiple genes or
variants are involved, additional studies on the functional effects per variant will aid in the
determination of which variant is more strongly contributing to the hearing loss phenotype.
5. Conclusions
We identified novel variants in 11 known genes for hearing loss and neurodevelop-
mental phenotypes. We also present three genes IST1, CBLN3 and GDPD5 as potential
candidate genes for hearing loss, all three of which have mouse models with abnormal ABR
findings that are matched to the patient’s genotype. Our findings highlight the importance
of identifying novel variants and genes in well-characterized patients from ethnic groups
that are understudied for hearing loss.
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